Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion launches Restora programme

Actelion launches Restora programme

21st December 2007

Actelion has launched its phase III programme Restora to investigate its orexin receptor antagonist almorexant.

The programme is intended to confirm the efficacy and safety of the drug in patients suffering from primary insomnia.

Over 670 patients will be enrolled into the programme across 70 clinical study areas in Asia, Europe, Israel and Latin America.

The company predicts the trial will confirm the effects of almorexant on sleep induction and sleep maintenance as shown in earlier studies.

Goran Hajak, professor of psychiatry at the University of Regensburg in Germany, illustrated that previous investigations found almorexant to be an effective agent that had initially demonstrated no side effects associated with currently available sleep agents.

Actelion’s chief executive officer Jean-Paul Clozel confirmed: “Actelion is committed to fully evaluating the potential role of almorexant in insomnia and beyond.”

Given the extensive pre-clinical data on the drug, almorexant has the potential to transform the healthcare’s approach to treating sleep disorders, he said.

Also this week, Actelion has announced that its headquarters, based in the Swiss town of Allschwil, is to celebrate its ten year anniversary.

The anniversary also marks the company’s move to becoming a full member of Interpharma – the association of Swiss pharmaceutical research companies.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.